Sugi Predict

Sugi Predict / Compounds / SCHEMBL2653775

SCHEMBL2653775

SCHEMBL2653775

O=[N+]([O-])c1cccc(-c2nn[nH]n2)c1

nearest known ligand 0.68

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ XDH P47989 1/20 0.67
▸ IDO1 P14902 2/20 0.60
▸ PDE3B Q13370 1/20 0.58
▸ PDE3A Q14432 1/20 0.58
▸ KDM4E B2RXH2 1/20 0.57
▸ MEN1 O00255 1/20 0.57
▸ ALOX12 P18054 1/20 0.57
▸ KMT2A Q03164 1/20 0.57
▸ KDM4C Q9H3R0 1/20 0.57
▸ GP6 Q9HCN6 1/20 0.57
▸ ALDH1A1 P00352 3/20 0.54
▸ F7 P08709 1/20 0.52
▸ LMNA P02545 3/20 0.51
▸ MAPT P10636 3/20 0.50
▸ NPC1 O15118 1/20 0.50
▸ RAB9A P51151 1/20 0.50
▸ SMN1; SMN2 Q16637 1/20 0.50
▸ CYP1A2 P05177 1/20 0.49
▸ TSHR P16473 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17834028 0.83 XDH (0.70) XDHIDO1PDE3BPDE3AKDM4E
SCHEMBL1250484 0.80 XDH (1.00) XDHPDE3BPDE3AKDM4EMEN1
SCHEMBL1247681 0.78 XDH (0.58) XDHKDM4EMEN1KMT2AALDH1A1
SCHEMBL2157222 0.77 XDH (0.65) XDHIDO1KDM4EMEN1ALOX12
SCHEMBL6738366 0.75 TSHR (0.76) IDO1MEN1KMT2AALDH1A1LMNA
SCHEMBL20242176 0.75 IDO1 (0.56) IDO1MEN1KMT2AALDH1A1LMNA
SCHEMBL27743881 0.75 CYP1A2 (0.59) IDO1ALDH1A1LMNAMAPTNPC1
SCHEMBL2646724 0.75 GP6 (0.66) XDHIDO1MEN1KMT2AGP6
SCHEMBL25440198 0.74 CYP1A2 (0.55) IDO1KMT2AALDH1A1LMNAMAPT
SCHEMBL18262990 0.74 KDM4E (0.81) XDHIDO1KDM4EMEN1ALOX12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117106189-A Metal organic framework artificial hydrolase and preparation method and application thereof 华南理工大学 2023-11-24 — — CN claimed
US-20250074919-A1 Heteroaryl compounds as inhibitors of irak4, compositions and applications thereof ACCRO BIOSCIENCE HK LTD (HK) 2025-03-06 — — US disclosed
EP-4456895-A2 HETEROARYL COMPOUNDS AS INHIBITORS OF IRAK4, COMPOSITIONS AND APPLICATIONS THEREOF Accro Bioscience (HK) Limited (HK) 2024-11-06 — — EP disclosed
CN-117106189-A Metal organic framework artificial hydrolase and preparation method and application thereof 华南理工大学 2023-11-24 — — CN disclosed
WO-2023130054-A2 HETEROARYL COMPOUNDS AS INHIBITORS OF IRAK4, COMPOSITIONS AND APPLICATIONS THEREOF ACCRO BIOSCIENCE (HK) LIMITED (CN) 2023-07-06 — — WO disclosed
EP-3054955-B1 PYRROLOTRIAZINE KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2018-05-30 — — EP disclosed
US-20180057465-A1 Inhibitors of Necroptosis CATALYST THERAPEUTICS PTY LTD (AU) 2018-03-01 — — US disclosed
US-20180057465-A1 Inhibitors of Necroptosis CATALYST THERAPEUTICS PTY LTD (AU) 2018-03-01 — — US disclosed
US-20180057465-A1 Inhibitors of Necroptosis CATALYST THERAPEUTICS PTY LTD (AU) 2018-03-01 — — US disclosed
EP-3256452-A1 INHIBITORS OF NECROPTOSIS Catalyst Therapeutics Pty Ltd. (AU) 2017-12-20 — — EP disclosed
WO-2013056079-A1 HIGH AFFINITY BETA LACTAMASE INHIBITORS THE JOHNS HOPKINS UNIVERSITY (US) 2013-04-18 — — WO disclosed
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists NOVO NORDISK A/S (DK) 2009-06-04 — — US disclosed
EP-1183229-B1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK AS (DK) 2005-10-26 — — EP disclosed
US-20050203108-A1 Glucagon antagonists/inverse agonists PFIZER INC 2005-09-15 — — US disclosed
US-6875760-B2 Glucagon antagonists/inverse agonists NOVO NORDISK A/S (DK) 2005-04-05 — — US disclosed
US-20030220350-A1 Glucagon antagonists/inverse agonists PFIZER INC 2003-11-27 — — US disclosed
US-6503949-B1 Treating Type 2 diabetes, hyperglycemia, impaired glucose tolerance or obesity NORO NORDISK A/S (DK) 2003-01-07 — — US disclosed
CN-1356977-A Glucagon antagonists/inverse agonists NOVO NORDISK AS (DK) 2002-07-03 — — CN disclosed
EP-1183229-A1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK A/S (DK) 2002-03-06 — — EP disclosed
WO-2000069810-A1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK A/S (DK) 2000-11-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250074919-A1 Heteroaryl compounds as inhibitors of irak4, compositions and applications thereof IRAK4, IRAK1, IRAK2 XDH 2120/4885IDO1 2239/4885PDE3B 3429/4885
US-20050203108-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR XDH 2778/4885IDO1 2277/4885PDE3B 367/4885
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists GLP1R, GPR119, GCGR XDH 2778/4885IDO1 2277/4885PDE3B 367/4885
US-20030220350-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR XDH 2778/4885IDO1 2277/4885PDE3B 367/4885
US-20180057465-A1 Inhibitors of Necroptosis RIPK3, RIPK1, AIFM1 XDH 1453/4885IDO1 3049/4885PDE3B 2982/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.